Amira Pharmaceuticals, Roche deal

ROCZ and Amira partnered to develop compounds to treat inflammatory diseases. ROCZ will screen its compound repository against three targets provided by Amira, which will then optimize resulting leads. ROCZ will have opt-in rights on two of the three programs. If ROCZ exercises both options, Amira could receive up to $287 million in milestones, plus royalties. ...